On January 2, 2018 Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, reported that the company is scheduled to present and subsequently participate in a Q&A session at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 9:30 a.m. PT (12:30 p.m. ET) (Press release, Magenta Therapeutics, JAN 2, 2019, View Source [SID1234532357]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and Q&A session can be accessed under the "Events & Presentations" page within the Investors & Media section of the Magenta Therapeutics website at View Source A replay of the webcast will be available on the Magenta Therapeutics website for 90 days following the event.